losartan and Atrophic Muscular Disorders

losartan has been researched along with Atrophic Muscular Disorders in 1 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research

Studies (1)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Change From Baseline in Isokinetic Strength

"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 16 (i.e., baseline minus week 16) was the outcome of the analysis. A negative number indicates decrease in strength from week 0 to week 16." (NCT01989793)
Timeframe: Baseline to Week 16

Change From Baseline in Isokinetic Strength

"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 24 (i.e., baseline minus week 24) was the outcome of the analysis. A negative number indicates a decrease in strength from week 0 to week 24." (NCT01989793)
Timeframe: Baseline to Week 24

Change From Baseline in Isokinetic Strength

"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 8 (i.e., baseline minus week 8) was the outcome of the analysis. A negative number indicates that there was a decrease in isokinetic strength from week 0 to week 8." (NCT01989793)
Timeframe: Baseline to Week 8

Fatiguability

"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 16

Fatiguability

"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 24

Fatiguability

"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to the total work in the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 8

Number of Participants Experiencing Any Amount of Decrease in Frailty

Number of participants experiencing any amount of decrease in frailty score from baseline to Week 16 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 16 weeks

Number of Participants Experiencing Any Amount of Decrease in Frailty

Number of participants experiencing any amount of decrease in frailty score from baseline to Week 24 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 24 weeks

Number of Participants Experiencing Any Amount of Decrease in Frailty

Number of participants experiencing any amount of decrease in frailty score from baseline to Week 8 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 8 weeks

Other Studies

1 other study available for losartan and Atrophic Muscular Disorders